Faster Pace For Duchenne MD Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Six-minute walk test proves itself in boys’ genetic disease, too.
You may also be interested in...
PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
With FDA approval of the six-minute walk test as primary endpoint, private specialty firm hopes to bring first Duchenne muscular dystrophy drug to market within two years.
PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
With FDA approval of the six-minute walk test as primary endpoint, private specialty firm hopes to bring first Duchenne muscular dystrophy drug to market within two years.
PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
Despite targeting an indication with a very small population, PTC Therapeutics has fully enrolled a pivotal trial for ataluren (PTC124), its potential disease-modifying therapy for Duchenne muscular dystrophy, and expects to produce top-line data early next year. Regulatory filings in the U.S. and EU could follow closely if the data are promising